Clin Oncol | Volume 6, Issue 1 | Review Article | Open Access
Sumati Sundaraiya1* and Rajasekhar Perumalla2
1Department of Nuclear Medicine, Apollo Proton Cancer Centre Chennai, India
2Department of Hepatobiliary and Transplant Surgery, Fortis Hospital, India
*Correspondance to: Sumati SundaraiyaFulltext PDF
Transarterial radioembolization has emerged over the last decade as an established locoregional therapy for the management of primary and metastatic liver cancers, with hepatocellular carcinoma accounting for majority of primary liver cancers. TARE began as a treatment for advanced HCC in a palliative setting in patients with intermediate and advanced stage unresectable HCC that over the years has evolved as a curative treatment option. This review discusses the current evidence of TARE in clinical practice, concept of radiation segmentectomy, radiation lobectomy, and its role in tumors other than hepatocellular carcinoma and on personalized dosimetry.
Transarterial radioembolization; Radiation segmentectomy; Radiation lobectomy; Dosimetry
Sundaraiya S, Perumalla R. Current Status of TARE (Trans Arterial Radioembolization) in Clinical Practice – A Review. Clin Oncol. 2021;6:1823..